Viral Decay Acceleration™(VDA)

An Entirely New Approach to the Treatment of Antiviral Infections

KP-1461 is designed to provoke the rapid decay of the HIV virus by accelerating the rate at which the virus mutates.

KP-1461 has the potential to be an ART sparing regimen that could defer the initiation of anti-retroviral therapy against HIV.

The results from the initial Phase II study demonstrate that KP-1461 causes an accumulation of mutations leading to a virologic response (G-to-A and A-to-G base transformations); is safe and well-tolerated; and does not provoke cross-resistance to conventional nucleosides or other ART drugs.

A second Phase II study is planned to determine the length of time necessary for an accumulation of mutations to cause a collapse in a patient’s viral population.

There is a growing need for new antiviral therapeutics. Although there are more than 20 approved drugs to treat HIV infection, resistance development affects all of them and is the leading cause of treatment failure.